

CURRICULUM VITAE

Tao Wang PhD

Professor
Department of Data Science Institute

OFFICE ADDRESS:

8701 Watertown Plank Road

Milwaukee, WI 53226

Phone: +1 (414) 9554339

Email: taowang@mcw.edu

EDUCATION:

08/1979 - 07/1983 BS, Peking University, Beijing, P.R.China

08/1987 - 07/1990 MS, Southeast University, Nanjing, P.R.China

08/1990 - 07/1993 PhD, Southeast University, Nanjing, P.R.China

09/1997 - 12/2001 PhD, North Carolina State University, Raleigh, NC.

FACULTY APPOINTMENTS:

08/1993 - 12/1995 Lecturer, Institute of Systems Engineering, Southeast University, Nanjing, P.R.China

01/1996 - 05/1997 Assistant Professor, Institute of Systems Engineering, Southeast University, Nanjing, P.R.China

01/2002 - 06/2009 Assistant Professor, WI, Division of Biostatistics, Medical College of Wisconsin

07/2009 - 06/2025 Associate Professor, WI, Division of Biostatistics, Medical College of Wisconsin

07/2025 - Present Professor, WI, Division of Biostatistics, Medical College of Wisconsin

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:

1998 - 2003 Sigma Xi (the Scientific Research Society)

2001 - Present International Biometric Society (ENAR)

2002 - 2013 American Society of Human Genetics (ASHG)

2005 - Present American Statistical Association (ASA)

2007 - 2010 American Society for Bone and Marrow Transplantation (ASBMT)

2017 - 2019 Genetic Society of America (GSA)

BIBLIOGRAPHY

Refereed Journal Publications/Original Papers

1. **Wang T***, Sheng ZH, Cao X. Harris ergodicity of non-linear time series models (in Chinese). Journal of Southeast University, 21(1): 121-125. 1991.
2. Sheng ZH, **Wang T**, Liu DL*. A sufficient condition for non-ergodicity of a class of non-linear time series models (in Chinese). Mathematica Applicata, 7(3): 280-286. 1994.
3. **Wang T***, Sheng ZH. Non-existence of stationary distributions for a class of time-invariant non-linear stochastic difference equations (in Chinese). Journal of Southeast University, 24(1): 83-89. 1994.
4. **Wang T***, Sheng ZH. Asymptotic stationarity for a class of time-invariant non-linear stochastic difference equations (in Chinese). Journal of Southeast University, 24(2): 71-77. 1994.
5. **Wang T***, Sheng ZH. Stability of discrete-time stochastic systems (in Chinese). Journal of Systems Engineering, 9(2): 43-52. 1994.
6. **Wang T***, Sheng ZH. Stability of a class of large-scale discrete-time stochastic systems. Journal of Southeast University (English Edition), 11(1): 101-108. 1995.
7. **Wang T***, Sheng ZH. Asymptotic stationarity of discrete-time stochastic neural networks. Neural Networks,

- 9(6): 957-963. 1996.
8. Bilusic M, Bataillard A, Tschannen M, Gao L, Barreto N, Vincent M, **Wang T**, Jacob HJ, Sassard J, Kwitek AE. Hypertension and related phenotypes cluster on chromosome 2, 13 and 17 in the Lyon Hypertensive (LH) rat. *Hypertension*, 44: 695-701. 2004.
 9. Kugathasan S, Loizides A, Babusukumar U, McGuire E, **Wang T**, Hooper P, Nebel J, Kofman G, Noel R, Broeckel U, Tolia V. Comparative phenotypic and CARD15 mutational analysis among African American, Hispanic, and White children with Crohn's disease. *Inflammatory Bowel Diseases*, 11(7): 631-638. 2005.
 10. Zeng ZB*, **Wang T**, Zou W. Modeling quantitative trait loci and interpretation of models. *Genetics*, 169:1711-1725, 2005 (~ 192 citations)
 11. **Wang T***, Zeng ZB. Models and partition of variance for quantitative trait loci with epistasis and linkage disequilibrium. *BMC Genetics*, 7: Article 9. 2006.
 12. **Wang T***, Weir BS, Zeng ZB. A population-based latent variable approach for association mapping of quantitative trait loci. *Annals of Human Genetics*, 70(4): 506-523. 2006.
 13. Babusukumar U, **Wang T**, McGuire E, Miranda A, Broeckel U, Kugathasan S. Contribution of OCTN variants within the IBD5 locus in pediatric onset Crohn's disease. *American Journal of Gastroenterology*, 101(6): 1354-1361. 2006.
 14. Koukouritaki SB, Poch MT, Henderson MC, Siddens LK, Krueger SK, VanDyke JE, Williams DE, Pajewski NM, **Wang T**, Hines RN. Identification and functional analysis of common human flavin-containing monooxygenase 3 (FMO3) genetic variants. *The Journal of Pharmacology and Experimental Therapeutics*, 320(1): 266-273. 2007.
 15. Biank V, Friedrichs F, Babusukumar U, **Wang T**, Stoll M, Broeckel U, Kugathasan S. DLG5 R30Q Variant is a female-specific protective factor in pediatric onset Crohn's disease. *American Journal of Gastroenterology*, 102(2): 391-398. 2007.
 16. Glisic-Milosavljevic S, **Wang T**, Koppen M, Kramer J, Ehlenbach S, Waukau J, Jailwala P, Jana S, Alemzadeh R, Ghosh S. Dynamic changes in CD4+CD25+high T cell apoptosis after the diagnosis of type 1 diabetes. *Clinical and Experimental Immunology*, 150 (1): 75-82. 2007.
 17. Moreno C, Kaldunski ML, **Wang T**, Roman RJ, Greene AS, Lazar J, Jacob HJ, Cowley AW. Multiple blood pressure loci on rat chromosome 13 attenuate the development of hypertension in the Dahl S hypertensive rat. *Physiological Genomics*, 31(2): 228-235. 2007.
 18. Duquesnoy R, Spellman S, Haagenson M, **Wang T**, Horowitz MM, Oudshoorn M. HLA matchmaker-defined triplet matching is not associated with better survival rates of patients with class I HLA allele mismatched hematopoietic cell transplants from unrelated donors. *Biol Blood Marrow Transplant*, 14(9): 1064-1071. 2008.
 19. Adamovic T, McAllister D, Rowe J, **Wang T**, Jacob HJ, Sugg SL. Genetic mapping of mammary tumor traits to rat chromosome 10 using a novel panel of consomic rats. *Cancer Genetics and Cytogenetics*, 186(1): 41-48. 2008.
 20. Lee SJ, Kukreja M, **Wang T**, Giralt SA, Szer J, Arora M, Woolfrey AE, Cervantes F, Champlin RE, Gale RP, Halter J, Keating A, Marks DI, McCarthy PL, Olavarria E, Stadtmauer EA, Abecasis M, Gupta V, Khoury HJ, George B, Hale GA, Liesveld JL, Rizzieri DA, Antin JH, Bolwell BJ, Carabasi MH, Copelan E, Ilhan O, Litzow MR, Schouten HC, Zander AR, Horowitz MM, Maziarz RT. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. *Blood*. 112(8): 3500-3507. 2008.
 21. **Wang T***, Jacob H, Ghosh S, Wang XJ, Zeng ZB. A joint association test for multiple SNPs in genetic case-control studies. *Genetic Epidemiology*, 33(2): 151-163. 2009.
 22. **Wang T***, Zeng ZB. Contribution of genetic effects to genetic variance components with epistasis and linkage disequilibrium. *BMC Genetics*, 10: Article 52. 2009.
 23. Davies SM, Wang D, **Wang T**, Arora M, Ringden O, Anasetti C, Pavletic S, Casper J, MacMillan ML, Sanders J, Wall D and Kernan NA. Recent decrease in acute GVHD in children with leukemia receiving unrelated donor bone marrow transplants. *Biol Blood Marrow Transplant*, 15(3): 360-366. 2009.
 24. Ringden O, Pavletic S, Anasetti C, Barrett JA, **Wang T**, Wang D, Antin JH, Bartolomeo PD, Bolwell BJ, Bredeson C, Cairo MS, Gale RP, Gupta V, Hahn T, Hale GA, Halter J, Jagasia M, Litzow MR, Locatelli F, Marks DI, McCarthy PL, Cowan MJ, Petersdorf EW, Russell JA, Schiller GJ, Schouten H, Spellman S, Verdonck LF, Wingard JR, Horowitz MM, and Arora M. The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. *Blood*. 113(13): 3110-3118. 2009.

25. Glisic S, Klinker M, Waukau J, Jailwala P, Jana S, Basken J, **Wang T**, Alemzadeh R, Ghosh S. Genetic association of HLA DQB1 with CD4+CD25+high T-cell apoptosis in Type 1 Diabetes. *Genes and Immunology*, 10(4): 334-340. 2009.
26. Spellman S, Warden MB, Haagenson M, Pietz BC, Goulmy E, Warren E, **Wang T**, Ellis TM. Effects of mismatching for minor histocompatibility antigens on clinical outcomes in HLA-matched, unrelated hematopoietic stem cell transplants. *Biol Blood Marrow Transplant*, 15(7): 856-863. 2009.
27. Baxter-Lowe LA, Maiers M, Spellman S, Haagenson M, **Wang T**, Fernandez-Vina M, Marsh S, Horowitz M, Hurley CK, HLA-A disparities illustrate challenges for ranking the impact of HLA mismatches on Bone Marrow transplant outcomes in the United States. *Biol Blood Marrow Transplant*, 15(8): 971-981. 2009.
28. Anderson EJ, Grzywacz B, Wang H, **Wang T**, Haagenson M, Spellman S, Blazar BR, Miller JS, Verneris MR. Limited role of MHC class I chain-related gene A (MICA) typing in assessing GVHD risk after fully HLA-matched unrelated donor transplantation. *Blood*. 114(21): 4753-4754. 2009.
29. Klinker MW, Schiller JJ, Magnuson VL, **Wang T**, Basken J, Veth K, Pearce KI, Kinnunen L, Harjutsalo V, Wang XJ, Tuomilehto J, Sarti C, Ghosh S. Single-nucleotide polymorphisms in the IL2RA gene are associated with age-at-diagnosis in late-onset Finnish type 1 diabetes subjects. *Immunogenetics*, 62(2): 101-107. 2010.
30. McDermott DH, Conway SE, **Wang T**, Ricklefs SM, Agovi M, Porcella SF, Tran HTB, Milford E, Spellman S and Abdi R. Donor and recipient chemokine receptor CCR5 genotype is associated with survival after bone marrow transplantation. *Blood*. 115(11) :2311-2318. 2010.
31. Nguyen YP, Al-Lehibi A, Gorbe E, Li E, Haagenson M, **Wang T**, Spellman S, Lee SJ, and Davidson NO. Insufficient Evidence for Association of NOD2/CARD15 or Other Inflammatory Bowel Disease-Associated Markers on GVHD Incidence or Other Adverse Outcomes in T-Replete, Unrelated Donor Transplantation. *Blood*. 115(17): 3625-31. 2010.
32. Marks DI, **Wang T**, Perez WS, Antin JH, Copelan EA, Gale RP, George B, Gupta V, Halter J, Khoury HJ, Klumpp TR, Lazarus HM, Lewis VA, McCarthy PL, Rizzieri DA, Sabloff M, Szer J, Tallman MS, and Weisdorf DJ. The outcome of full intensity versus reduced intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome negative acute lymphoblastic leukemia in first and second complete remission. *Blood*. 116(3): 366-74, 2010.
33. Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, **Wang T**, Le CT, Marsh SGE, Geraghty DE, Spellman S, Haagenson MD, Ladner M, Trachtenberg EA, Parham P, and Miller JS. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. *Blood*. 116 (14): 2411-2419. 2010.
34. Adamovic T, McAllister D, **Wang T**, Adamovic D, Rowe JJ, Moreno C, Lazar J, Jacob HJ, Sugg SL. Identification of novel carcinogen-mediated mammary tumor susceptibility loci in the rat using the chromosome substitution technique. *Genes, Chromosomes and Cancer*, 49(11): 1035-45. 2010.
35. **Wang T***. On coding genotypes for genetic markers with multiple alleles in genetic association study of quantitative traits. *BMC Genetics*, 12: Article 82. 2011.
36. Valcárcel D, Sierra J, **Wang T**, Kan F, Gupta V, Hale GA, Marks DI, McCarthy PL, Oudshoorn M, Petersdorf EW, Ringdén O, Setterholm M, Spellman SR, Waller EK, Gajewski JL, Marino SR, Senitzer D, Lee SJ. One antigen mismatched related vs. HLA-matched unrelated donor hematopoietic transplantation in adults with acute leukemia: CIBMTR results in the era of molecular HLA typing. *Biology of Blood and Marrow Transplantation*, 17(5): 640-648. 2011.
37. Vogl DT, **Wang T**, Pérez WS, Stadtmauer EA, Heitjan DF, Lazarus HM, Kyle RA, Kamble R, Weisdorf D, Roy V, Gibson J, Ballen K, Holmberg L, Bashey A, McCarthy PL, Freytes C, Maharaj D, Maiolino A, Pavlovsky S, Hari P. Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma. *Biology of Blood and Marrow Transplantation*, 17(12): 1765-74. 2011.
38. Vierra-Green C, Roe D, Hou LH, Hurley CK, Rajalingam R, Reed E, Lebeveda T, Yu N, Stewart M, Noreen H, Hollenbach JA, M, Guethlein L, **Wang T**, Spellman S, Maiers M. Allele-level haplotype frequencies and pairwise linkage disequilibrium for 14 KIR loci in 506 European-American individuals. *PLOS One*, 7(11): e47491. 2012.
39. Khoury HJ, Kukreja M, Goldman JM, **Wang T**, Halter J, Arora M, Gupta V, Rizzieri DA, George B, Keating A, Gale RP, Marks DI, McCarthy PL, Woolfrey A, Szer J, Giralt SA, Maziarz RT, Cortes J, Horowitz MM, Lee SJ. Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis. *Bone Marrow Transplantation*, 47(6): 810-816. 2012.
40. Petersdorf EW, Malkki M, Gooley TA, Spellman SR, Haagenson MD, Horowitz MM, **Wang T**. MHC

- resident variation affects risks after unrelated donor Hematopoietic cell transplantation. *Science Translational Medicine*, 4(144): 144ra101. 2012.
41. Battiwalla M, **Wang T**, Carreras J, Deeg HJ, Ayas M, Bajwa RP, George B, Gupta V, Pasquini R, Schrezenmeier H, Passweg JR, Schultz KR, Eapen M. HLA-matched sibling transplantation for severe aplastic anemia: impact of HLA DR15 antigen status on engraftment, graft-versus-host disease, and overall survival. *Biology of Blood and Marrow Transplantation*. 18(9): 1401-1406. 2012.
 42. Horan J, **Wang T**, Haagenson MD, Spellman SR, Dehn J, Eapen M, Frangoul H, Gupta V, Hale GA, Hurley CK, Marino S, Oudshoorn M, Reddy V, Shaw P, Lee SJ, Woofrey A. Evaluation of HLA matching in unrelated hematopoietic stem cell transplantation for nonmalignant disorders. *Blood*. 120(14): 2918-2924. 2012.
 43. Logan BR*, **Wang T**. Pseudo-value regression models. In *Handbook of Survival Analysis*. Editors: Klein JP, van Houwelingen HC, Ibrahim JG, Scheike TH, Pages 199-219. Chapman and Hall/CRC, 2013.
 44. Petersdorf EW, Malkki M, Horowitz MM, Spellman SR, Haagenson MD, **Wang T**. Mapping MHC haplotype effects in unrelated donor hematopoietic cell transplantation. *Blood*. 121(10): 1896-1905. 2013.
 45. Bedi M, King D, Shivakoti M, **Wang T**, Zambrano E, Charlson J, Hackbarth D, Neilson J, Whitfield R, Wang D. Prognostic variables in patients with primary soft tissue sarcoma of the extremity and trunk treated with neoadjuvant radiotherapy or neoadjuvant sequential chemoradiotherapy. *BMC Radiation Oncology*, 8: Article 60. 2013.
 46. Hurley CK, Woolfrey A, **Wang T**, Haagenson M, Umejiego J, Aljurf M, Askar M, Battiwalla M, Dehn J, Horan J, Oudshoorn M, Pidala J, Saber W, Turner V, Lee SJ, Spellman SR. The impact of HLA unidirectional mismatches on the outcome of myeloablative hematopoietic stem cell transplantation with unrelated donors. *Blood*. 121(23): 4800-4806. 2013.
 47. Chiu YE, Havens PL, Siegel DH, Ali O, **Wang T**, Holland KE, Galbraith SS, Lyon VB, Drolet BA. Serum 25-hydroxyvitamin D concentration does not correlate with atopic dermatitis severity. *Journal of the American Academy of Dermatology*, 69(1): 40-46. 2013.
 48. Shamim Z, Spellman S, Haagenson M, **Wang T**, Lee SJ, Ryder LP, Müller K. Polymorphism in the interleukin-7 receptor-alpha and outcome after allogeneic hematopoietic cell transplantation with matched unrelated donor. *Scand J Immunol*, 78(2): 214-220. 2013.
 49. Pidala J, **Wang T**, Haagenson M, Spellman S, Askar M, Battiwalla M, Baxter-Lowe LA, Bitan M, Fernandez-Vina MA, Gandhi M, Jakubowski A, Maiers M, Marino SR, Marsh SGE, Oudshoorn M, Palmer JM, Prasad V, Reddy V, Ringden O, Saber W, Santarone S, Schultz K, Setterholm M, Trachtenberg E, Turner EV, Woolfrey AE, Lee SJ, Anasetti C. Amino acid substitution at peptide-binding pockets of HLA class I molecules increases risk of severe acute GVHD and mortality. *Blood*. 122(22): 3651-3658. 2013.
 50. Mendolia F, Klein J, Petersdorf E, Malkki M, **Wang T***. Comparison of statistics in association tests of genetic markers for survival outcomes. *Statistics in Medicine*, 33: 828-844. 2014.
 51. **Wang T***. A revised Fisher model on analysis of quantitative trait loci with multiple alleles. *Frontiers in Genetics*, section Statistical Genetics and Methodology, 5: Article 328. 2014.
 52. Fernandez-Vina M, **Wang T**, Lee S, Haagenson M, Aljurf M, Askar M, Battiwalla M, Baxter-Lowe LA, Gajewski J, Jakubowski A, Marino S, Oudshoorn M, Marsh S, Petersdorf E, Schultz K, Turner EV, Waller E, Woolfrey A, Umejiego JB, Spellman S, Setterholm MI. Identification of a Permissible HLA Mismatch in Hematopoietic Stem Cell Transplantation. *Blood*. 123(8): 1270-8. 2014.
 53. Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, **Wang T**, Marsh SGE, Spellman S, Haagenson MD, Saetern K, Ladner M, Trachtenberg E, Parham P, Miller JS. Donor killer-cell immunoglobulin-like receptor B haplotypes, recipient HLA-C1 and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia. *The Journal of Immunology*, 192(10): 4592-4600. 2014.
 54. Sengsayadeth S, **Wang T**, Lee SJ, Haagenson MD, Spellman S, Fernandez-Viña MA, Muller CR, Verneris MR, Savani BN, Jagasia M. Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) Single Nucleotide Polymorphisms Do Not Impact Outcomes after Unrelated Donor Transplant: A Center for International Blood and Marrow Transplant Research Analysis. *Biology of Blood and Marrow Transplantation*, 20(6): 900-903. 2014.
 55. Fleischhauer K, Fernandez-Viña MA, **Wang T**, Haagenson M, Battiwalla M, Baxter-Lowe LA, Ciceri F, Dehn J, Gajewski J, Hale GA, Heemskerk MBA, Marino SR, McCarthy PL, Miklos D, Oudshoorn M, Pollack MS, Reddy V, Senitzer D, Shaw BE, Waller EK, Lee SJ, Spellman SR. Risk associations between HLA-DPB1 T cell epitope matching and outcome of unrelated hematopoietic cell

- transplantation are independent from HLA-DPA1. *Bone Marrow Transplantation*, 49(9): 1176-1183. 2014.
56. Hill GD, Hehir DA, Bartz PJ, Rudd NA, Frommelt MA, Slicker J, Tanem J, Frontier K, Xiang Q, **Wang T**, Tweddell JS, Ghanayem NS. Effect of feeding modality on interstage growth following stage I palliation: a report from the National Pediatric Cardiology Quality Improvement Collaborative. *The Journal of Thoracic and Cardiovascular Surgery*, 148(4): 1534-1539. 2014.
 57. Broux B, Shamim Z, **Wang T**, Spellman S, Haagenson M, Stinissen P, Ryder LP, Müller K, Hellings N. The influence of interleukin 7 receptor γ chain haplotypes on outcome after allogeneic hematopoietic cell transplantation. *International Journal of Immunogenetics*, 41(6): 521-527. 2014.
 58. **Wang T***, He P, Ahn KW, Wang X, Ghosh S, Laud P. A re-formulation of generalized linear mixed models to fit family data in genetic association studies. *Frontiers in Genetics*, section Statistical Genetics and Methodology, 6: Article 120. 2015.
 59. Kornblit B, Enevold C, **Wang T**, Spellman S, Haagenson M, Lee SJ and Müller K. Toll like receptor polymorphisms in allogeneic hematopoietic cell transplantation. *Biol Blood Marrow Transplant*, 21(2): 259-65. 2015 (Received the Karl Blume Award from BBMT)
 60. Arai S, Arora M, **Wang T**, Spellman SR, He W, Couriel DR, Urbano-Ispizua A, Cutler CS, Bacigalupo AA, Battiwalla M, Flowers ME, Juckett MB, Lee SJ, Loren AW, Klumpp TR, Prockup SE, Ringdén OT, Savani BN, Socié G, Schultz KR, Spitzer T, Teshima T, Bredeson CN, Jacobsohn DA, Hayashi RJ, Drobyski WR, Frangoul HA, Akpek G, Ho VT, Lewis VA, Gale RP, Koreth J, Chao NJ, Aljurf MD, Cooper BW, Laughlin MJ, Hsu JW, Hematti P, Verdonck LF, Solh MM, Norkin M, Reddy V, Martino R, Gadalla S, Goldberg JD, McCarthy PL, Pérez-Simón JA, Khera N, Lewis ID, Atsuta Y, Olsson RF, Saber W, Waller EK, Blaise D, Pidala JA, Martin PJ, Satwani P, Bornhäuser M, Inamoto Y, Weisdorf DJ, Horowitz MM, Pavletic SZ. Increasing Incidence of Chronic Graft-versus-Host Disease in allogeneic transplantation - a report from CIBMTR. *Biol Blood Marrow Transplant*, 21(2): 266-274. 2015.
 61. Bachanova V, Burns L, **Wang T**, Carreras J, Gale R, Wiernik P, Ballen K, Wirk B, Munker R, Chen YB, Gibson J, Akpek G, Costa L, Kamble R, Aljurf MD, Hsu J, Cairo M, Schouten H, Bacher U, Savani B, Wingard J, Lazarus H, Rizzieri D, Laport G, Montoto S, Maloney D, Brunstein C, Saber W. Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor. *Bone Marrow Transplantation*, 50(2): 197-203. 2015.
 62. Gadalla SM, **Wang T**, Haagenson M, Spellman SR, Lee SJ, Williams KM, Wong JY, Vivo ID, Savage SA. Association between donor leukocyte telomere length and survival after unrelated allogeneic hematopoietic cell transplantation for severe aplastic anemia. *The Journal of the American Medical Association (JAMA)*, 313(6): 594-602. 2015.
 63. Sobecks RM, **Wang T**, Askar M, Gallagher MM, Haagenson M, Spellman S, Fernandez-Vina M, Malmberg KJ, Muller C, Battiwalla M, Gajewski J, Verneris MR, Ringden O, Marino SR, Davies S, Dehn J, Bornhäuser M, Inamoto Y, Woolfrey A, Shaw P, Pollack M, Weisdorf D, Miller J, Hurley CK, Lee SJ, Hsu KC. Impact of KIR and HLA genotypes on outcomes after reduced-intensity conditioning hematopoietic cell transplantation. *Biol Blood Marrow Transplant*, 21(9):1589-1596. 2015.
 64. Inamoto Y, Flowers ME, **Wang T**, Urbano-Ispizua A, Hemmer MT, Cutler CS, Couriel DR, Alousi AM, Antin JH, Gale RP, Gupta V, Hamilton BK, Kharfan-Dabaja MA, Marks DI, Ringdén OT, Socié G, Solh MM, Akpek G, Cairo MS, Chao NJ, Hayashi RJ, Nishihori T, Reshef R, Saad A, Shah A, Teshima T, Tallman MS, Wirk B, Spellman SR, Arora M, Martin PJ. Tacrolimus versus cyclosporine after hematopoietic cell transplantation for acquired aplastic anemia. *Biol Blood Marrow Transplant*, 21(10): 1776-1782. 2015.
 65. Petersdorf EW, Malkki M, O'hUigin C, Carrington M, Gooley T, Haagenson MD, Horowitz MM, Spellman SR, **Wang T**, Stevenson P. High HLA-DP expression and graft-versus-host disease. *New England Journal of Medicine (NEJM)*, 373(7): 599-609. 2015.
 66. Knight JM, Rizzo JD, Logan BR, **Wang T**, Arevalo JMG, Ma J, Cole SW. Low socioeconomic status, adverse gene expression profiles, and clinical outcomes in hematopoietic stem cell transplant recipients. *Clinical Cancer Research*, 22(1):69-78. 2015.
 67. Huang XY, Yuan TZ, Liang MH, Du MJ, Xia S, Dittmar R, Wang D, See W, Costello BA, Quevedo F, Tan W, Nandy D, Bevan GH, Longenbach S, Sun ZF, Lu Y, **Wang T**, Thibodeau SN, Boardman L, Kohli M, Wang L. Exosomal miR-1290 and miR-375 as Prognostic Markers in Castration-resistant Prostate Cancer. *European Urology*, 67(1): 33-41. 2015.
 68. Jindra PT, Conway SE, Ricklefs SM, Porcella SF, Anzick SL, Haagenson M, **Wang T**, Spellman S, Milford E, Kraft P, McDermott DH, Abdi R. Analysis of a genetic polymorphism in the costimulatory

- molecule TNFSF4 with HSCT outcomes. *Biol Blood Marrow Transplant*, 22(1):27-36. 2016.
69. Nakasone H, Sahaf B, Tian L, **Wang T**, Haagenson MD, Schoenrock K, Perloff S, Ryan CE, Wu F, Spellman SR, Lee SJ, Ritz J, Miklos DB. Presensitization to HY antigens in female donors prior to transplant is not associated with male recipient post-transplant HY antibody development nor with clinical outcomes. *Haematologica*, 101(1):e30-33. 2016.
70. Lazaryan A, **Wang T**, Spellman SR, Wang H-L, Pidala J, Nishihori T, Askar M, Olsson R, Oudshoorn M, Abdel-Azim H, Yong A, Gandhi M, Dandoy C, Savani B, Hale G, Page K, Bitan M, Reshef R, Drobyski W, Marsh SGE, Schultz K, Müller CR, Fernandez-Viña M, Verneris MR, Horowitz MM, Arora M, Weisdorf DJ, Lee SJ. Human leukocyte antigen supertype matching after myeloablative hematopoietic cell transplantation with 7/8 matched unrelated donor allografts: A report from the Center for International Blood and Marrow Transplant Research. *Haematologica*, 101(10):1267-1274. 2016.
71. Du M, Tillmans L, Gao J, Gao P, Yuan T, Dittmar RL, Song W, Yang Y, Sahr N, **Wang T**, Wei GH, Thibodeau SN, Wang L. Chromatin interactions and candidate genes at ten prostate cancer loci. *Scientific Reports*, 6: Article 23202. 2016.
72. Rocha V, Ruggeri A, Spellman S, **Wang T**, Sobecks R, Locatelli F, Askar M, Michel G, Arcese W, Iori AP, Purtill D, Danby R, Sanz GF, Gluckman E, Eapen M. Killer cell immunoglobulin-like receptor ligand matching and outcomes after unrelated cord blood transplantation acute myeloid leukemia. *Biol Blood Marrow Transplant*, 22(7):1284-1289. 2016.
73. Arora M, Lee SJ, Spellman SR, Weisdorf DJ, Guan W, Haagenson M, **Wang T**, Horowitz MH, Verneris MR, Fleischhauer K, Hsu K, Thyagarajan B. A validation study failed to confirm an association between genetic variants in the base excision repair pathway and TRM and relapse after HCT. *Biol Blood Marrow Transplant*, 22(8):1531-1532. 2016.
74. Bachanova V, Weisdorf DJ, **Wang T**, Marsh SGE, Trachtenberg E, Haagenson MD, Spellman SR, Ladner M, Guethlein LA, Parham P, Miller JS, Cooley SA. Donor KIR B genotype improves progression free survival of non-Hodgkin lymphoma patients receiving unrelated donor transplantation. *Biol Blood Marrow Transplant*, 22(9): 1602-1607. 2016.
75. Marino SR, Lee S, Binkowski A, **Wang T**, Haagenson M, Wang H, Maiers M, Spellman S, Besien kv, Lee S, Karrison T, Artz A. Identification of high-risk amino acid substitutions in hematopoietic cell transplantation: a challenging task. *Bone Marrow Transplantation*, 51(10):1342-1349. 2016.
76. Kornblit B, **Wang T**, Lee SJ, Spellman SR, Zhu X, Fleischhauer K, Müller C, Verneris MR, Müller K, Johansen JS, Vindelov L, Garred P. Donor YKL-40 levels are associated with graft versus host disease after allogeneic hematopoietic cell transplantation. *Bone Marrow Transplantation*, 51(12): 1556-1569. 2016.
77. Gadalla SM, **Wang T**, Dagnall C, Haagenson M, Spellman SR, Hicks B, Jones K, Katki HA, Lee SJ, Savage SA. Effect of recipient age and stem cell source on the Association between donor telomere length and survival after allogeneic unrelated hematopoietic cell transplantation for severe aplastic anemia. *Biol Blood Marrow Transplant*, 22(12): 2276-2282. 2016.
78. Tarima S*, He P, **Wang T**, Szabo A. An interim sample size recalculation for observational studies. *Observational Studies*, 2: 65-85. 2016.
79. **Wang T***. Analysis of variance components for genetic markers with unphased genotypes. *Frontiers in Genetics*, section Statistical Genetics and Methodology, 7: Article 123. 2016.
80. Hoff GA, Fischer JC, Hsu K, Bergerson R, Cooley S, Miller JS, **Wang T**, Haagenson M, Spellman S, Lee SJ, Uhrberg M, Venstrom JM, Verneris MR. Recipient HLA-C haplotypes and miRNA 148a/b binding sites have no impact on allogeneic hematopoietic cell transplantation outcomes. *Biol Blood Marrow Transplant*, 23(1):153-160. 2017.
81. Goyal R, Lee S, **Wang T**, Trucco M, Haagenson M, Spellman S, Verneris M, Ferrell R. Novel HLA-DP region susceptibility loci associated with severe acute graft-versus-host-disease. *Bone Marrow Transplantation*, 52(1): 95-100. 2017.
82. Chen YB, **Wang T**, Hemmer MT, Brady C, Couriel DR, Alousi A, Pidala J, Urbano-Ispizua A, Choi SW, Nishihori T, Teshima T, Inamoto Y, Wirk B, Marks DI, Abdel-Azim H, Lehmann L, Yu L, Bitan M, Cairo MS, Qayed M, Salit R, Gale RP, Martino R, Jaglowski S, Bajel A, Savani B, Frangoul H, Lewis ID, Storek J, Askar M, Kharfan-Dabaja MA, Aljurf M, Ringden O, Reshef R, Olsson RF, Hashmi S, Seo S, Spitzer TR, MacMillan ML, Lazaryan A, Spellman SR, Arora M, Cutler CS. GVHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes. *Bone Marrow Transplantation*, 52(3): 400-408. 2017.
83. Lindsley RC, Saber W, Mar BG, Redd R, **Wang T**, Haagenson MD, Grauman PV, Hu ZH, Spellman SR,

- Lee SJ, Verneris MR, Hsu K, Fleischhauer K, Cutler C, Antin JH, Neuberg D, Ebert BL. Prognostic mutations in Myelodysplastic syndrome after stem cell transplantation. *New England Journal of Medicine (NEJM)*, 376(6): 536-547. 2017.
84. Askar M, Sobecks R, **Wang T**, Haagenson M, Majhail N, Madbouly A, Thomas D, Zhang A, Fleischhauer K, Hsu K, Verneris M, Lee SJ, Spellman SR and Fernández-Viña M. MHC Class I Chain-Related Gene A (MICA) Donor-Recipient Mismatches and MICA-129 Polymorphism in Unrelated Donor Hematopoietic Cell Transplants (HCT) for Hematological Malignancies: A CIBMTR Study. *Biol Blood Marrow Transplant*, 23(3): 436-444. 2017.
85. Khoury HJ, **Wang T**, Hemmer MT, Couriel D, Alousi A, Cutler C, Aljurf M, Antin JH, Ayas M, Battiwalla M, Cahn JY, Cairo M, Chen YB, Gale RP, Hashmi S, Hayashi RJ, Jagasia M, Juckett M, Kamble RT, Kharfan-Dabaja M, Litzow M, Majhail N, Miller A, Nishihori T, Qayed M, Schoemans H, Schouten HC, Socie G, Storek J, Verdonck L, Vij R, Wood WA, Yu L, Martino R, Carabasi R, Dandoy C, Gergis U, Hematti P, Solh M, Jamani K, Lehmann L, Savani B, Schultz KR, Wirk BM, Spellman S, Arora M, Pidala J. Improved survival after acute graft vs. host disease diagnosis in the modern era. *Haematologica*, 102(5): 958-966. 2017.
86. Madbouly A, **Wang T**, Haagenson M, Paunic V, Vierra-Green C, Katharina Fleischhauer K, Hsu KC, Verneris MR, Majhail NS, Lee SJ, Spellman SR, Maiers M. Investigating the association of genetic admixture and donor/recipient genetic disparity with transplant outcomes. *Biol Blood Marrow Transplant*, 23(6): 1029-1037. 2017.
87. Wang Y, **Wang T**, Dagnall C, Haagenson M, Spellman SR, Hicks B, Jones K, Lee SJ, Savage SA, Gadalla SM. Relative telomere length prior to hematopoietic cell transplantation (HCT) and outcome after unrelated donor HCT for acute leukemia. *Biol Blood Marrow Transplant*, 23(7): 1054-1058. 2017.
88. Eapen M, **Wang T**, Veys PA, Boelens JJ, Martin AS, Spellman S, Bonfim CS, Brady C, Cant A, Dalle JH, Davies SM, Freeman J, Hsu KC, Fleischhauer K, Kenzey C, Kurtzberg J, Michel G, Orchard PJ, Paviglianiti A, Rocha V, Verneris MR, Volt F, Wynn R, Lee SJ, Horowitz MM, Gluckman E, Ruggeri A. Allele-level HLA matching for umbilical cord blood transplantation for nonmalignant diseases in children: a retrospective analysis. *The Lancet Haematology*, 4(7): e325-e333. 2017.
89. Krakow EF, Hemmer M, **Wang T**, Logan B, Aurora M, Spellman S, Last M, Lachance S, Moodie E. Tools for the precision medicine era: how to develop highly personalized treatment recommendations from cohort and registry data using Q-learning. *American Journal of Epidemiology (AJE)*, 186(2): 160-172. 2017 (Awarded as one of the 10 best Articles of the Year in AJE)
90. Gadalla S, **Wang T**, Loftus D, Friedman L, Dagnall C, Haagenson M, Spellman S, Buturovic L, Blauwkamp M, Shelton J, Fleischhauer K, Hsu K, Verneris M, Krstajic D, Hicks B, Jones K, Lee S, Savage S. No association between donor telomere length and outcomes after allogeneic unrelated hematopoietic cell transplant in patients with acute leukemia. *Bone Marrow Transplantation*, 53(4): 383-391. 2018.
91. Turcotte L, **Wang T**, Hemmer M, Spellman S, Arora M, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Beitinjaneh A, Buchbinder D, Byrne M, Callander N, Chao NJ, Choi SW, DeFilipp Z, Gadalla S, Gale R, Gergis U, Hashmi S, Hematti P, Holmberg L, Inamoto Y, Kamble R, Lehmann L, MacMillan M, McIver Z, Nishihori T, Norkin M, O'Brien T, Olsson R, Reshef R, Saad A, Savani B, Schouten H, Seo S, Solh M, Verdonck LF, Vij R, Wirk B, Yared J, Horowitz M, Knight J, Ahmed I, Verneris M. Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation. *Bone Marrow Transplantation*, 53(7): 932-937. 2018. .
92. Cheng Y, Song HY, Pan XQ, Xue H, Wan YF, **Wang T**, Tian ZM, Hou ET, Lanza IR, Liu PY, Liu Y, Laud PW, Usa K, He YC, Liang MY. Urinary Metabolites Associated with Blood Pressure on a Low- or High-Sodium Diet. *Theranostics*, 8(6): 1468-1480. 2018.
93. Qayed M, **Wang T**, Hemmer MT, Spellman SR, Arora M, Couriel DR, Alousi AM, Pidala J, Abdel-Azim H, Aljurf M, Ayas M, Bitan M, Cairo M, Choi SW, Dandoy C, Delgado D, Gale RP, Hale G, Frangoul H, Kamble RT, Kharfan-Dabaja M, Lehman L, Levine J, MacMillan M, Marks DI, Nishihori T, Olsson RF, Hematti P, Ringden O, Saad A, Satwani P, Savani BN, Schultz KR, Seo S, Shenoy S, Waller EK, Yu L, Horowitz MM, Horan J. Influence of age on acute and chronic GVHD in children undergoing HLA-identical sibling BMT for acute leukemia: implications for prophylaxis. *Biol Blood Marrow Transplantation*, 24(3): 521-528. 2018.
94. William BM, **Wang T**, Haagenson MD, Fleischhauer K, Verneris M, Hsu K, de Lima MJ, Fernandez-Vina M, Spellman SR, Lee SJ, Hill BT. Impact of human leukocyte antigen (HLA) alleles on outcomes of allogeneic transplantation for B-cell non-Hodgkin lymphomas: A Center for International Blood and Marrow Transplant Research Analysis. *Biol Blood Marrow Transplant*, 24(4): 827-831. 2018.
95. Gadalla S, Aubert G, **Wang T**, Haagenson M, Spellman S, Wang LX, Katki H, Savage S, Lee S. Donor

- telomere length and causes of death after unrelated hematopoietic cell transplant in patients with marrow failure. *Blood*. 131(21): 2393-2398. 2018.
96. Buturovic L, Shelton J, Spellman SR, **Wang T**, Friedman L, Loftus D, Hesterberg L, Woodring T, Fleischhauer K, Hsu KC, Verneris MR, Haagenson M, Lee SJ. Evaluation of a machine learning-based prognostic model for unrelated hematopoietic cell transplantation donor selection. *Biol Blood Marrow Transplant*. 24(6): 1299-1306. 2018.
 97. Petersdorf E, Stevenson P, Malkki M, Strong R, Spellman S, Haagenson M, Horowitz M, Gooley T, **Wang T**. Patient HLA germline variation and transplant survivorship. *Journal of Clinical Oncology (JCO)*. 36(24): 2524-2531. 2018.
 98. Wang Y, Zhou W, Alter BP, **Wang T**, Spellman SR, Haagenson M, Yeager M, Lee SJ, Chanock SJ, Savage SA, Gadalla SM. Chromosomal aberrations and survival after unrelated donor hematopoietic stem cell transplant in patients with Fanconi anemia. *Biol Blood Marrow Transplant*. 24(10): 2003-2008. 2018.
 99. Nikiforow S, **Wang T**, Hemmer M, Spellman S, Akpek G, Antin JH, Choi SW, Inamoto Y, Khoury HJ, MacMillan M, Marks DI, Meehan K, Nakasone H, Nishihori T, Olsson R, Paczesny S, Przepiorka D, Reddy V, Reshef R, Schoemans H, Waller N, Weisdorf D, Wirk B, Horowitz M, Alousi A, Couriel D, Pidala J, Arora M, Cutler C. Upper gastrointestinal acute graft-versus-host disease adds minimal prognostic value in isolation or with other graft-versus-host disease symptoms as currently diagnosed and treated. *Haematologica*. 103(10): 1708-1719. 2018.
 100. Turcotte LM, **Wang T**, Hemmer MT, Spellman SR, Arora M, Yingst A, Couriel D, Alousi A, Pidala J, Knight JM, Verneris MR. Pro-inflammatory Cytokine and adipokine levels in adult unrelated marrow donors are not associated with Hematopoietic cell transplantation outcomes. *Biol Blood Marrow Transplant*. 25(1): 12-18. 2019.
 101. Weisdorf D, Cooley S, **Wang T**, Trachtenberg E, Haagenson MD, Vierra-Green C, Spellman SR, Spahn A, Vogel J, Kobusingye H, Fehninger T, Woolfrey A, Devine S, Ross M, Waller EK, Sobecks R, Parham P, Guethlein LA, Marsh SGE, Miller J. KIR donor selection: feasibility in identifying better donors. *Biol Blood Marrow Transplant*. 25(1): e28-e32. 2019.
 102. Woolfrey A, **Wang T**, Lee SJ, Haagenson MD, Chen G, Fleischhauer K, Horan J, Hsu K, Verneris M, Spellman SR, Fernandez-Vina M. Donor-specific anti-HLA antibodies in unrelated hematopoietic cell transplantation for non-malignant disorders. *Bone Marrow Transplantation*. 54(3): 494-496. 2019.
 103. Pingel J, **Wang T**, Hagenlocher Y, Hernández-Frederick CJ, Nagler A, Haagenson MD, Fleischhauer K, Hsu KC, Verneris MR, Lee SJ, Mohty M, Polge E, Spellman SR, Schmidt AH, van Rood JJ. The effect of NIMA matching in adult unrelated mismatched hematopoietic stem cell transplantation - a joint study of the acute leukemia working party of the EBMT and the CIBMTR. *Bone Marrow Transplantation*. 54(6): 849-857. 2019.
 104. Alousi A, **Wang T**, Hemmer MT, Spellman SR, Arora M, Couriel DR, Pidala J, Anderlini P, Boyiadzis M, Bredeson CN, Cahn J-Y, Cairo MS, Gadalla SM, Hashmi SK, Gale RP, Kanda J, Kamble RT, Kharfan-Dabaja MA, Litzow MR, Ringden O, Saad A, Schultz KR, Verdonck LF, Waller EK, Yared JA, Holtan SG, Weisdorf DJ. Peripheral blood versus bone marrow from unrelated donors: bone marrow allografts have improved long-term overall and graft-versus-host disease, relapse-free survival. *Biol Blood Marrow Transplant*. 25(2): 270-278. 2019.
 105. Askar M, Sayer D, **Wang T**, Haagenson M, Spellman SR, Lee SJ, Madbouly A, Fleischhauer K, Hsu KC, Verneris MR, Thomas D, Zhang A, Sobecks R, Majhail NS. Analysis of single nucleotide polymorphisms in the gamma block of the major histocompatibility complex in association with clinical outcomes of hematopoietic cell transplantation: A CIBMTR study. *Biol Blood Marrow Transplant*. 25(4): 664-672. 2019.
 106. Bachanova V, Weisdorf DJ, **Wang T**, Marsh SGE, Cereb N, Haagenson MD, Spellman SR, Lee SJ, Guethlein LA, Parham P, Miller JS, Cooley S. Donor killer-cell immunoglobulin-like receptor (KIR) genotype does not improve graft-versus-leukemia responses in chronic lymphocytic leukemia (CLL) after unrelated donor transplant: a CIBMTR analysis. *Biol Blood Marrow Transplant*. 25(5): 949-954. 2019.
 107. McCune JS, **Wang T**, Bo-Subait K, Aljurf M, Beitinjaneh A, Bubalo J, Cahn J-Y, Cerny J, Chhabra S, Cumpston A, Dupuis LL, Lazarus HM, Marks DI, Maziarz RT, Norkin M, Prestidge T, Mineishi S, Krem MM, Pasquini M, Martin PJ. Association of antiepileptic medications with outcomes after allogeneic hematopoietic cell transplantation with busulfan/cyclophosphamide conditioning. *Biol Blood Marrow Transplant*. 25(7): 1424-1431. 2019.
 108. Saad A, Hashmi S, Lamb L, **Wang T**, Hemmer MT, Arora M, Spellman S, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Agrawal V, Aljurf M, Beitinjaneh AM, Bhatt VR, Buchbinder D, Byrne M, Cahn JY,

- Cairo M, Castillo P, Chhabra S, Diaz MA, Farhan S, Floisand Y, Hadar A, Frangoul, Gadalla S, Gajewski J, Gale RP, Gandhi M, Gergis U, Hamilton BK, Hematti P, Hildebrandt GC, Kamble RT, Kanate AS, Khandelwal P, Lazaryn A, MacMillan M, Marks DI, Martino P, Mehta PA, Nishihori T, Olsson RF, Patel S, Qayed M, Rangarajan HG, Reshef R, Ringden O, Savani BN, Schouten HC, Schultz KR, Seo S, Shaffer B, Solh M, Urbano-Ispizua TT, Verdonck L, Vij R, Waller EK, William B, Wirk B, Yared JA, Yu LC. Impact of T-cell dose on the outcome of T-cell replete HLA matched allogeneic peripheral blood stem cell transplantation. *Biol Blood Marrow Transplant*. 25(9): 1875-1883. 2019.
109. Tsamadou C, Fürst D, **Wang T**, He N, Lee SJ, Spellman SR, Fleischhauer K, Hsu KC, Paczesny S, Verneris MR, Neuchel C, Schrezenmeier H, Mytilineos J. Donor HLA-E status associates with disease free survival and transplant related mortality after non in vivo T-cell depleted HSCT for Acute Leukemia. *Biol Blood Marrow Transplant*. 25(12): 2357-2365. 2019.
110. Sabloff M, Chhabra S, **Wang T**, Fretham S, Kekre N, Abraham A, Adekola K, Auletta JJ, Barker C, Beitinjaneh AM, Bredeson C, Cahn JY, Diaz MA, Freytes C, Gale RP, Ganguly S, Gergis U, Guinan E, Hamilton B, Hashmi S, Hematti P, Hildebrandt G, Holmberg L, Hong S, Lazarus HM, Martino R, Muffly L, Nishihori T, Perales MA, Yared J, Mineishi S, Stadtmauer EA, Pasquini MC, Loren AW. Comparison of high doses of total body irradiation in myeloablative conditioning prior to hematopoietic cell transplantation. *Biol Blood Marrow Transplant*. 25(12): 2398-2407. 2019.
111. Mehta RS, Holtan SG, **Wang T**, Hemmer MT, Spellman SR, Arora M, Couriel DR, Alousi AM, Pidala J, Abdel-Aziz H, Ahmed I, Aljurf M, Askar M, Auletta JJ, Bhatt V, Bredeson C, Chhabra S, Gadalla S, Gajewski J, Gale RP, Gergis U, Hematti P, Hildebrandt GC, Inamoto Y, Kitko C, Khandelwal P, MacMillan ML, Majhail N, Marks DI, Mehta P, Nishihori T, Olsson RF, Pawarode A, Diaz MA, Prestidge T, Qayed M, Rangarajan H, Ringden O, Saad A, Savani BN, Seo S, Shah S, Shah N, Schultz KR, Solh M, Spitzer T, Szer J, Teshima T, Verdonck L, Williams KM, Wirk B, Wagner J, Yared JA, Weisdorf DJ. GRFS and CRFS in Alternative Donor Hematopoietic Cell Transplantation for Pediatric Patients with Acute Leukemia. *Blood Advances*. 3(9): 1441-1449. 2019.
112. Tang H, Hahn T, Karaesmen E, Rizvi AA, Wang J, Paczesny S, **Wang T**, Preus L, Zhu Q, Wang Y, Haiman CA, Stram D, Pooler L, Sheng X, Van Den Berg D, Brock G, Webb A, Pasquini MC, McCarthy PL, Spellman SR, Sucheston-Campbell LE. Validation of genetic associations with acute GVHD and nonrelapse mortality in DISCOVERY-BMT. *Blood Advances*. 3(15): 2337-2341. 2019.
113. Karaesmen E, Hahn T, Dile AJ, Rizvi AA, Wang J, **Wang T**, Haagenson MD, Preus L, Zhu Q, Liu Q, Yan L, Liu S, Haiman CA, Stram D, Pooler L, Sheng X, Van Den Berg D, Brock G, Webb A, McCarthy PL, Pasquini MC, Spellman SR, Lee SJ, Paczesny S, Sucheston-Campbell LE. Multiple functional variants in the IL1RL1 region are pretransplant markers for risk of GVHD and infection deaths. *Blood Advances*. 3(16): 2512-2524. 2019.
114. Knight JM, Rizzo JD, **Wang T**, He N, Logan BR, Spellman SR, Lee SL, Verneris MR, Arevalo JMG, Cole SW. Molecular correlates of socioeconomic status predict acute myelogenous leukemia relapse following hematopoietic cell transplantation. *JNCI Cancer Spectrum*. 3(4): pkz073. 2019.
115. Grosshuesch C, Johnson WK, DeVogel N, Yin Z, **Wang T**, Kindel SJ, Woods RK. Brain Death Interval and Relationship to Outcomes of Pediatric Cardiac Transplantation. *Pediatric Transplantation*. 23(4): e13426. 2019.
116. **Wang T***, DeVogel N. A revisit to two-way factorial ANOVA with mixed effects and interactions. *Communications in Statistics - Theory and Methods*. 49(19): 4618-4635. 2020.
117. Weisdorf D, Cooley S, **Wang T**, Trachtenberg E, Vierra-Green C, Spellman S, Sees J, Spahn A, Vogel J, Fehninger T, Woolfrey A, Devine S, Ross M, Waller E, Sobecks R, McGuirk J, Slack J, Brunvand M, Bachier C, Oran B, Farag S, Shore T, Besien KV, Marsh S, Parham P, Guethlein L, Miller J. KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplant. *Blood Advances*. 4(4): 740-754. 2020.
118. Verneris MR, Miller JS, Hsu KC, **Wang T**, Sees JA, Paczesny S, Rangarajan H, Lee DA, Spellman SR, Lee SJ. Investigation of donor KIR content and matching in children undergoing hematopoietic cell transplantation for acute leukemia. *Blood Advances*. 4(7): 1350-1356. 2020.
119. Wang Y, McReynolds LJ, Dagnall C, Katki HA, Spellman SR, **Wang T**, Hicks B, Freedman ND, Jones K, Lee SJ, Savage SA, Gadalla SM. Pre-transplant short telomeres are associated with high mortality risk after unrelated donor hematopoietic cell transplant for severe aplastic anemia. *British Journal of Hematology*. 188(2): 309-316. 2020.
120. McReynolds LJ, Wang Y, Thompson AS, Ballew BJ, Kim J, Alter BP, Hicks B, Zhu B, Jones K, Spellman SR, **Wang T**, Lee SJ, Savage SA, Gadalla S. Population frequency of Fanconi pathway gene variants

- and their association with survival after hematopoietic cell transplant for severe aplastic anemia. *Biol Blood Marrow Transplant*. 26(5): 817-822. 2020.
121. Isaacson E, Lucjak C, Johnson WK, Yin ZY, **Wang T**, Rein L, Woods RK, Tweddell JS, Hraska V, Mitchell ME. Mitral valve surgery in neonates, infants and children: surgical approach, outcomes, and predictors. *Seminars in Thoracic and Cardiovascular Surgery*. 32(3): 541-550. 2020.
 122. Savage SA, Viard M, O'hUigin C, Zhou W, Yeager M, Li SA, **Wang T**, Ramsuran V, Vince N, Vogt A, Hicks B, Burdett L, Chung C, Dean M, de Andrade KC, Freedman ND, Berndt S, Rothman N, Lan Q, Cerhan JR, Slager SL, Zhang Y, Teras LR, Haagenson M, Chanock SJ, Spellman SR, Wang Y, Willis A, Askar M, Lee SJ, Carrington M, Gadalla SM. Genome-wide association study identifies HLA-DPB1 as a significant risk factor for severe aplastic anemia. *American Journal of Human Genetics (AJHG)*. 106(2): 264-271. 2020.
 123. Mehta RS, Holtan SG, **Wang T**, Hemmer MT, Spellman SR, Arora M, Couriel DR, Alousi AM, Pidala J, Abdel-Azim H, Ahmed I, Aljurf M, Askar M, Auletta JJ, Bhatt VR, Chhabra S, Gajewski J, Gale RP, Gergis U, Hematti P, Hildebrandt GC, Inamoto Y, Majhail N, Marks DI, Nishihori T, Olsson RF, Pawarode A, Diaz MA, Prestidge T, Rangarajan H, Ringden O, Saad A, Savani BN, Seo S, Schultz KR, Solh M, Spitzer T, Teshima T, Verdonck L, Wirk B, Weisdorf DJ. Composite GRFS and CRFS outcomes after adult alternative donor HCT. *Journal of Clinical Oncology (JCO)*. 38(18):2062-2076. 2020.
 124. Im A, Rashidi A, **Wang T**, Hemmer M, MacMillan ML, Pidala J, Jagasia M, Pavletic S, Majhail NS, Weisdorf D, Abdel-Azim H, Agrawal V, Al-Homsi AS, Aljurf M, Askar M, Auletta JJ, Bashey A, Beitinjaneh A, Bhatt VR, Byrne M, Cahn JY, Cairo M, Castillo P, Cerny J, Chhabra S, Choe H, Ciurea S, Daly A, Perez MAD, Farhadfar N, Gadalla SM, Gale R, Ganguly S, Gergis U, Hanna R, Hematti P, Herzig R, Hildebrandt GC, Lad DP, Lee C, Lehmann L, Lekakis L, Kamble RT, Kharfan-Dabaja MA, Khandelwal P, Martino R, Murthy HS, Nishihori T, O'Brien TA, Olsson RF, Patel SS, Perales MA, Prestidge T, Qayed M, Romee R, Schoemans H, Seo S, Sharma A, Solh M, Strair R, Teshima T, Urbano-Ispizua A, Van der Poel M, Vij R, Wagner JL, William B, Wirk B, Yared JA, Spellman SR, Arora M, Hamilton BK. Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation using Post-Transplant Cyclophosphamide. *Biol Blood Marrow Transplant*. 26(8): 1459-1468. 2020.
 125. Gadalla SM, Wang Y, **Wang T**, Onabajo OO, Banday AR, Obajemu A, Karaesman E, Sucheston-Campbell L, Hahn T, Sees JA, Spellman SR, Lee SJ, Katki HA, Prokunina-Olsson L. Donor IFNL4 genotype predicts non-relapse mortality after unrelated donor myeloablative hematopoietic cell transplantation for acute leukemia: A retrospective cohort study. *The Lancet Haematology*. 7(10): e715-e723. 2020.
 126. Kidambi S, **Wang T**, Chelius T, Nunuk I, Agarwal P, Laud P, Mattson D, Cowley AW, Liang MY, Kotchen T. Twenty-four-hour versus clinic blood pressure levels as predictors of long-term cardiovascular and renal disease outcomes among African Americans. *Scientific Reports*. 10(1): 11685. 2020.
 127. Myllymäki M, Redd R, Reilly C, Saber W, Spellman S, Gibson C, Hu ZH, **Wang T**, Orr E, Grenier J, Chen M, Steensma D, Cutler C, De Vivo I, Antin J, Neuberger S, Agarwal S, Lindsley RC. Short Telomere Length Predicts Non-Relapse Mortality after Stem Cell Transplantation for Myelodysplastic Syndrome. *Blood*. 136(26): 3070-3081. 2020.
 128. Nazha A, Hu Z-H, **Wang T**, Lindsley RC, Abdel-Azim H, Aljurf M, Bacher U, Bashey A, Cahn J-Y, Cerny J, Copelan E, DeFilipp Z, Diaz MA, Farhadfar N, Gadalla SM, Gale RP, George B, Gergis U, Grunwald MR, Hamilton B, Hashmi S, Hildebrandt GC, Inamoto Y, Kalaycio M, Kamble RT, Kharfan-Dabaja MA, Lazarus HM, Liesveld JL, Litzow MR, Majhail NS, Murthy HS, Nathan S, Nishihori T, Pawarode A, Rizzieri D, Sabloff M, Savani BN, Schachter L, Schouten HC, Seo S, Shah NN, Solh M, Valcárcel D, Vij R, Warlick E, Wirk B, Wood WA, Yared JA, Alyea E, Popat U, Sobecks R, Scott BL, Nakamura R, Saber W. A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Myelodysplastic Syndromes Patients. *Biol Blood Marrow Transplant*. 26(11): 2139-2146. 2020.
 129. DeVogel N, Auer PL, Manansala R, Rau A, **Wang T***. A unified linear mixed model for familial relatedness and population structure in genetic association studies. *Genetic Epidemiology*. 45 (3): 305-315. 2021.
 130. Dhakal B, **Wang T**, Kuxhausen M, Zhu F, Taylor C, Spellman SR, Verneris MR, Hsu K, Fleischhauer K, Lee SJ, Bolon Y-T, Carlson K-S, Nazha A, Saber W. Prognostic Impact of Serum CXCL4 and CXCL7 on Myelodysplastic Syndromes Post Allogeneic Hematopoietic Cell Transplant. *Leukemia & Lymphoma*. 62(1): 229-233. 2021.

131. Wang Y, Zhou W, Wang J, Karaesman E, Tang H, McCarthy PL, Pasquini MC, Wang Y, McReynolds LJ, Katki HA, Machiela MJ, Yeager M, Pooler L, Sheng X, Haiman CA, Van Den Berg D, Spellman SR, **Wang T**, Kuxhausen M, Chanock SJ, Lee SJ, Clay-Gilmore AI, Hahn TE, Gadalla SM, Sucheston-Campbell LE. Pre-HCT mosaicism increases relapse risk and lowers survival in acute lymphoblastic leukemia patients post-unrelated HCT. *Blood Advances*. 5(1): 66-70. 2021.
132. Camacho-Bydume C, **Wang T**, Sees JA, Fernandez-Viña M, Abid MB, Askar M, Beitinjaneh A, Brown V, Castillo P, Chhabra S, Gadalla SM, Hsu JM, Kamoun M, Lazaryan A, Nishihori T, Page K, Schetelig J, Fleischhauer K, Marsh SGE, Paczesny S, Spellman SR, Lee SJ, Hsu KC. Specific class I HLA supertypes but not HLA zygosity or expression are associated with outcomes following HLA-matched allogeneic hematopoietic cell transplant. *Transplantation and Cellular Therapy*. 27(2): 142.e1-142.e11. 2021.
133. Elgarten CW, Li Y, Getz KD, Hemmer M, Huang Y-SV, Hall M, **Wang T**, Kitko CL, Jagasia MH, Nishihori T, Murthy HS, Hashem H, Cairo MS, Sharma A, Hashmi SK, Askar M, Beitinjaneh A, Kelly MS, Auletta JJ, Badawy SM, Mavers M, Aplenc R, MacMillan ML, Spellman SR, Arora M, Fisher BT. Broad spectrum antibiotics and risk of graft-versus-host disease in pediatric patients transplanted for acute leukemia: association of carbapenem use with risk of acute GVHD. *Transplantation and Cellular Therapy*. 27(2): 177.e1-177.e8. 2021.
134. Alsaggaf R, Katta S, **Wang T**, Hicks BD, Zhu B, Spellman SR, Lee SJ, Horvath S, Gadalla SM. Epigenetic aging and hematopoietic cell transplantation in patients with severe aplastic anemia. *Transplantation and Cellular Therapy*. 27(4): 313.e1-313.e8. 2021.
135. Farhadfar N, Dias A, **Wang T**, Fretham C, Chhabra S, Murthy HS, Broglie L, D'Souza A, Gadalla SM, Gale RP, Hashmi S, Al-Homsi AS, Hildebrandt GC, Hematti P, Rizzieri D, Chee L, Lazarus HM, Bredeson C, Jaimes EA, Beitinjaneh A, Bashey A, Prestidge T, Krem MM, Marks DI, Benoit S, Yared JA, Nishihori T, Olsson RF, Freytes CO, Stadtmauer E, Savani BN, Sorrow ML, Ganguly S, Wingard JR, Pasquini M. Impact of pretransplantation renal dysfunction on outcomes after allogeneic hematopoietic cell transplantation. *Transplantation and Cellular Therapy*. 27(5): 410-422. 2021.
136. Mayor NP, **Wang T**, Lee SJ, Kuxhausen M, Vierra-Green C, Barker DJ, Auletta J, Bhatt VR, Gadalla SM, Gragert L, Inamoto Y, Morris GP, Paczesny S, Reshef R, Ringdén O, Shaw BE, Shaw P, Spellman SR, Marsh SGE. Impact of previously unrecognized HLA mismatches using ultra-high resolution typing in unrelated donor hematopoietic cell transplantation. *Journal of Clinical Oncology (JCO)*. 36 (24): 2524-2531. 2021.
137. Guethlein LA, Beyzaie N, Nemat-Gorgani N, **Wang T**, Ramesh V, Marin WM, Hollenbach JA, Schetelig J, Spellman S, Marsh SGE, Cooley S, Weisdorf DJ, Norman PJ, Miller JS, Parham P. Following transplantation for AML, donor KIR Cen B02 better protects against relapse than KIR Cen B01. *The Journal of Immunology*. 206(12): 3064-3072. 2021.
138. Story CM, **Wang T**, Bhatt VR, Battiwalla M, Badawy SM, Kamoun M, Gragert L, Brown V, Baxter-Lowe LA, Marsh SG, Gadalla SM, Schetelig J, Myilinos J, Miklos D, Waller E, Kuxhausen M, Spellman S, Lee S, Paczesny S, Lansford JL, Vincent BG, Riches ML, Armistead PM. Genetics of HLA peptide presentation and impact on outcomes in HLA-matched allo-HCT. *Transplantation and Cellular Therapy*. 27(7): 591-599. 2021.
139. Kidambi S, Pan XQ, Yang C, Liu PY, Roberts M, Li YC, **Wang T**, Laud P, Liu Y, Ruben M, Thomas R, Widlansky M, Beyer A, Liu Y, Cowley AW, Kotchen T, Munyura Y, Moosreiner A, Mattson D, Liang MY. Dietary Sodium restriction results in tissue-specific changes in DNA methylation in humans. *Hypertension*. 78(2): 434-446. 2021.
140. Wang Y, Zhou W, McReynolds LJ, Katki HA, Griffiths E, Thota S, Machiela MJ, Yeager M, McCarthy P, Pasquini MC, Wang J, Karaesman E, Rizvi A, Preus L, Tang H, Wang Y, Pooler L, Sheng X, Haiman CA, Van Den Berg D, Spellman SR, **Wang T**, Kuxhausen M, Chanock SJ, Lee SJ, Hahn TE, Sucheston-Campbell LE, Gadalla SM. Prognostic impact of pre-transplant chromosomal aberrations in peripheral blood of patients undergoing unrelated donor hematopoietic cell transplant for acute myeloid leukemia. *Scientific Reports*. 11(1): 15004. 2021.
141. Bhatt VR, **Wang T**, Chen K, Kitko CL, MacMillan ML, Pidala JA, Malki MMA, Badawy SM, Beitinjaneh A, Ganguly S, Hamilton B, Hildebrandt GC, Lekakis L, Liu H, Maziarz RT, Modi D, Murthy HS, Preussler JM, Sharma A, Spellman SR, Arora M, Lee SJ. Chronic Graft-Versus-Host Disease, Non-Relapse Mortality and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A CIBMTR Analysis. *Transplantation and Cellular Therapy*. 28(1): 34-42. 2022.
142. Zou J, **Wang T**, He M, Bolon YT, Gadalla SM, Marsh SGE, Kuxhausen M, Gale RP, Sharma A, Assal A,

- Prestidge T, Aljurf M, Cerny J, Paczesny S, Spellman SR, Lee SJ, Ciurea SO. Number of HLA mismatched eplets is not associated with major outcomes in haploidentical transplantation with post-transplantation cyclophosphamide: A Center for International Blood and Marrow Transplant Research Study. *Transplantation and Cellular Therapy*. 28(2): 107.e1-107.e8. 2022.
143. Roberts ML, Kotchen TA, Pan X, Li Y, Yang C, Liu P, **Wang T**, Laud PW, Chelius TH, Munyura Y, Mattson DL, Liu Y, Cowley AW Jr, Kidambi S, Liang M. Unique Associations of DNA Methylation Regions With 24-Hour Blood Pressure Phenotypes in Black Participants. *Hypertension*. 79(4): 761-772. 2022.
144. Fuchs EJ, McCurdy SR, Solomon SR, **Wang T**, Herr MM, Modi D, Grunwald MR, Nishihori T, Kuxhausen M, Fingerson S, McKallor C, Bashey A, Kasamon YL, Bolon Y-T, Saad A, McGuirk JP, Paczesny S, Gadalla SM, Marsh SG, Shaw BE, Spellman SR, Lee SJ, Petersdorf EW. HLA informs risk predictions after haploidentical stem cell transplantation with post-transplantation cyclophosphamide. *Blood*. 139 (10): 1452-1468. 2022. (highlighted by Blood Podcast)
145. Otegbeye F, Vina MAF, **Wang T**, Bolon YT, Lazaryan A, Beitinjaneh A, Raj V Bhatt, Castillo P, Marsh GE, Hildebrandt GC, Assal A, Brown VI, Hsu JM, Spellman S, Marcos de Lima, Lee SJ. Natural killer cell alloreactivity predicted by killer cell immunoglobulin-like receptor ligand mismatch does not impact engraftment in umbilical cord blood and haploidentical stem cell transplantation. *Transplantation and Cellular Therapy*. 28(8): 483.e1-483.e7. 2022.
146. Arrieta-Bolaños E, Crivello P, He M, **Wang T**, Gadalla SM, Paczesny S, Marsh SGE, Lee SJ, Spellman SR, Bolon Y-T, Fleischhauer K. A core group of structurally similar HLA-DPB1 alleles drives permissiveness after hematopoietic cell transplantation. *Blood*. 140(6):659-663. 2022.
147. McReynolds LJ, Rafati M, Wang Y, Ballew BJ, Kim J, Williams VV, Zhou W, Hendricks RM, Dagnall CL, Freedman ND, Carter B, Stollo S, Hicks B, Zhu B, Jones KM, Paczesny S, Marsh SGE, Spellman SR, He M, **Wang T**, Lee SJ, Savage SA, Gadalla SM. Genetic testing in severe aplastic anemia is required for optimal hematopoietic cell transplant outcomes. *Blood*. 140(8): 909-921. 2022.
148. Lee CJ, **Wang T**, Chen K, Arora M, Brazauskas R, Spellman SR, Kitko C, MacMillan ML, Pidala JA, Auletta JJ, Badawy SM, Bhatt N, Bhatt VR, Cahn JY, DeFilipp Z, Diaz MA, Farhadfar N, Gadalla S, Gale RP, Hashem H, Hashmi S, Hematti P, Hong S, Hossain NM, Inamoto Y, Lekakis LJ, Modi D, Patel S, Sharma A, Solomon S, Couriel DR. Association of chronic graft-versus-host disease with late effects following allogeneic hematopoietic cell transplantation for children with hematologic malignancy. *Transplantation and Cellular Therapy*. 28(10): 712.e1-712.e8. 2022.
149. Saliba RM, Majid AA, Pidala J, Arora M, Spellman SR, Hemmer MT, **Wang T**, Abboud C, Ahmed S, Antin JH, Beitinjaneh A, Buchbinder D, Byrne M, Cahn JY, Choe H, Hanna R, Hematti P, Kamble RT, Kitko CL, Laughlin M, Lekakis L, MacMillan ML, Martino R, Mehta PA, Nishihori T, Patel SS, Perales MA, Rangarajan HG, Ringdén O, Rosenthal J, Savani BN, Schultz KR, Seo S, Teshima T, van der Poel M, Verdonck LF, Weisdorf D, Wirk B, Yared JA, Schriber J, Champlin R, Ciurea S. Characteristics of graft-versus-host disease (GvHD) after post-transplant cyclophosphamide versus conventional GvHD prophylaxis. *Transplantation and Cellular Therapy*. 28(10): 681-693. 2022.
150. Brown DW, Zhou W, Wang Y, Jones K, Luo W, Dagnall C, Teshome K, Klein A, Zhang T, Lin SH, Lee OW, Khan S, Vo JB, Hutchinson A, Liu J, Wang J, Zhu B, Hicks B, Martin AS, Spellman SR, **Wang T**, Deeg HJ, Gupta V, Lee SJ, Freedman ND, Yeager M, Chanock SJ, Savage SA, Saber W, Gadalla SM, Machiela MJ. Germline-somatic JAK2 interactions are associated with clonal expansion in myelofibrosis. *Nature Communications*. 13(1): 5284. 2022.
151. DeVogel N, Auer PL, Manansala R, **Wang T***. On asymptotic distributions of several test statistics for familial relatedness in linear mixed models. *Statistics in Medicine*. 42 (17): 2962-2981. 2023.
152. Brazauskas R*, Eapen M, **Wang T**. Endpoint selection and evaluation in hematology studies. *Best Practice & Research Clinical Haematology*. 36(3): 101479. 2023. PMID: 37611997; PMCID: PMC10979628.
153. Crivello P, Arrieta-Bolaños E, He M, **Wang T**, Fingerson S, Gadalla SM, Paczesny S, Marsh SGE, Lee SJ, Spellman SR, Bolon YT, Fleischhauer K. Impact of the HLA immunopeptidome on survival of leukemia patients after unrelated donor transplantation. *J Clin Oncol (JCO)*. 41(13): 2416-2427. 2023.
154. Mussetti A, Kanate AS, **Wang T**, He M, Hamadani M, Finel H Sr, Boumendil A Sr, Glass B, Castagna L, Dominietto A, McGuirk J, Blaise D, Gülbas Z, Diez-Martin J, Marsh SGE, Paczesny S, Gadalla SM, Dreger P, Zhang MJ, Spellman SR, Lee SJ, Bolon YT, Sureda A. Haploidentical versus Matched Unrelated Donor Transplants Using Post-Transplantation Cyclophosphamide for Lymphomas. *Transplantation and Cellular Therapy*. 29 (3): 184.e1-184.e9. 2023.
155. Narayan R, Niroula A, **Wang T**, Kuxhausen M, He M, Meyer E, Chen YB, Bhatt VR, Beitinjaneh A, Nishihori T, Sharma A, Brown VI, Kamoun M, Diaz MA, Abid MB, Askar M, Kanakry CG, Gragert

- L, Bolon YT, Marsh SGE, Gadalla SM, Paczesny S, Spellman S, Lee SJ. HLA Class I genotype is associated with relapse risk after allogeneic stem cell transplantation for NPM1-mutated AML. *Transplantation and Cellular Therapy*. 29(7): 452.e1-452.e11. 2023.
156. Gillis N, Padron E, **Wang T**, Chen K, DeVos JD, Spellman SR, Lee SJ, Kitko CL, MacMillan ML, West J, Tang YH, Teng M, McNulty S, Druley TE, Pidala JA, Lazaryan A. Pilot Study of Donor-Engrafted Clonal Hematopoiesis Evolution and Clinical Outcomes in Allogeneic Hematopoietic Cell Transplantation Recipients Using a National Registry. *Transplantation and Cellular Therapy*. 29 (10): 640.e1-640.e8. 2023.
157. Rafati M, Brown DW, Zhou W, Jones K, Luo W, St Martin A, Wang Y, He M, Spellman SR, **Wang T**, Deeg HJ, Gupta V, Lee SJ, Bolon YT, Chanock SJ, Machiela MJ, Saber W, Gadalla SM. JAK2 V617F mutation and associated chromosomal alterations in primary and secondary myelofibrosis and post-HCT outcomes. *Blood Advances*. 7(24): 7506-7515. 2023.
158. **Wang T*** and Lin CW. Using a centered general linear model for detection of interactions among biomarkers. *Statistical Methods in Medical Research*. 33(3): 414-432. 2024.
159. Fein JA, Shouval R, Krieger E, Spellman SR, **Wang T**, Baldauf H, Fleischhauer K, Kröger N, Horowitz M, Maiers M, Miller JS, Mohty M, Nagler A, Weisdorf D, Malmberg KJ, Toor AA, Schetelig J, Romee R, Koreth J. Systematic evaluation of donor-KIR/recipient-HLA interactions in HLA-matched hematopoietic cell transplantation for AML. *Blood Advances*. 8(3): 581-590. 2024.
160. Lee CJ, **Wang T**, Chen K, Arora M, Brazauskas R, Spellman SR, Kitko C, MacMillan ML, Pidala JA, Badawy SM, Bhatt N, Bhatt VR, DeFilipp Z, Diaz MA, Farhadfar N, Gadalla S, Hashmi S, Hematti P, Hossain NM, Inamoto Y, Lekakis LJ, Sharma A, Solomon S, Lee SJ, Couriel DR. Severity of Chronic Graft-versus-Host Disease and Late Effects Following Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancy. *Transplantation and Cellular Therapy*. 30(1): 97.e1-97.e14. 2024.
161. Webster AP, Ecker S, Moghul I, Liu X, Dhami P, Marzi S, Paul DS, Kuxhausen M, Lee SJ, Spellman SR, **Wang T**, Feber A, Rakyan V, Peggs KS, Beck S. Donor whole blood DNA methylation is not a strong predictor of acute graft versus host disease in unrelated donor allogeneic haematopoietic cell transplantation. *Frontiers in Genetics*. 15: Article 1242636. 2024. PMID: 38633407; PMCID: PMC11021570.
162. Turcotte LM, **Wang T**, Beyer KM, Cole SW, Spellman SR, Allbee-Johnson M, Williams E, Zhou Y, Verneris MR, Rizzo JD, Knight JM. The health risk of social disadvantage is transplantable into a new host. *Proceedings of the National Academy of Sciences (PNAS)*. 121(30): e2404108121. 2024. PMID: 39008669.
163. Pandya BJ, Burns LJ, **Wang T**, Xie B, Touya M, Spalding J, Block A, Kuperman G, Young C. Clinical outcomes and treatment patterns in adults with FLT3-ITDmut+ acute myeloid leukemia undergoing allogeneic hemopoietic cell transplantation in the US and Canada. *Transplantation and Cellular Therapy*. 30(7): 683.e1-683.e13. 2024. PMID: 38663769.
164. Farhadfar N, Rashid N, Chen K, DeVos JD, **Wang T**, Ballen KK, Beitinjaneh A, Bhatt VR, Hamilton BK, Hematti P, Gadalla SM, Solomon SR, El Jurdi N, Lee CJ, MacMillan ML, Rangarajan HG, Schoemans HM, Sharma A, Spellman SR, Wingard JR, Lee SJ. Racial, ethnic and socioeconomic diversity and outcomes of patients with graft-versus-host disease: A CIBMTR analysis. *Blood Advances*. 8(18):4963-4976, 2024. PMID: 38776400.
165. Mehta R, Petersdorf E, **Wang T**, Spellman S, Lee S. Interplay between donor age and HLA-DP matching in 10/10 HLA-matched unrelated donor HCT. *Blood Advances*. 8(20):5438-5449. 2024. PMID: 39008717; PMCID: PMC11568750.
166. Mehta R, Petersdorf E, **Wang T**, Spellman S, Lee S. Haploidentical versus mismatched unrelated donor HCT: HLA-factors and donor age considerations. *Transplantation and Cellular Therapy*. 30(9): 909.e1-909.e11, 2024. PMID: 38992469.
167. Ballen K, **Wang T**, He N, Knight JM, Hong S, Frangoul H, Verdonck LF, Steinberg A, Diaz MA, LeMaistre CF, Badaway SM, Pu JJ, Hashem H, Savani B, Sharma A, Lazarus HM, Abid MB, Tay J, Rangarajan HG, Kindwall-Keller T, Freytes CO, Beitinjaneh A, Winestone LE, Gergis U, Farhadfar N, Bhatt NS, Schears R, Gómez-Almaguer D, Aljurf M, Agrawal V, Kuwatsuka Y, Seo S, Marks DI, Lehmann L, Wood WA, Hashmi S, Saber W. Impact of race/ethnicity on outcomes after umbilical cord blood transplantation. *Transplantation and Cellular Therapy*. 30(10): 1027.e1-1027.e14, 2024. PMID: 39033978. PMCID: PMC11842128.
168. Baxter-Lowe LA, **Wang T**, Kuxhausen M, Spellman SR, Maiers M, Lee S, Saultz J, Arrieta-Bolaños E, Gadalla SM, Bolon YT, Betts BC. Novel Scoring System for Ranking Hematopoietic Stem Cell

- Transplantation. *Clin Transplant*. 38(11): e15478, 2024. PMID: 39512128. PMC11840805.
169. Wallis W, Gulbis AM, **Wang T**, Lee CJ, Sharma A, Williams KM, Nishihori T, Prestidge T, Gowda L, Byrne M, Krem MM, MacMillan ML, Kitko CL, Pidala J, Spellman SR, Lee SJ, Alousi AM. Incidence of bacterial blood stream infections in patients with acute GVHD. *Bone Marrow Transplant*. 60 (2): 175-177, 2025. PMID: 39420192. PMC11724748.
170. Mehta R, Sparapani R, **Wang T**, Spellman S, Lee S, Petersdorf E. Donor Age Matters for Haploidentical HCT Patients Even after Adjusting for HLA Factors: A Machine Learning Approach. *American J Hematology*. 100(5):937-940. 2025. PMID: 40056061. PMC12288135.
171. Mehta RS, Schmidt G, Williams K, Patel SA, Schetelig J, Savani B, Askar M, Petersdorf E, Ringden O, Kanakry CG, Kanakry JA, Stefanski H, Arrieta-Bolaños E, Betts B, Benjamin C, Gadalla S, **Wang T**, Saultz J, Spellman S, Jurdi NE, Bolon YT, Lee SJ. Choosing between HLA-Mismatched Unrelated and Haploidentical donors: Donor age considerations. *Transplantation and Cellular Therapy*. 31(9):680-692. 2025 PMID: 40419020. PMC12403200.
172. Bhasin-Chhabra B, **Wang T**, Levine JE, Shenoy S, Perales MA, Bashey A, Raff H, Saber W. Soluble Urokinase Plasminogen Activator Receptor and Acute Kidney Injury in Hematopoietic Cell Transplantation. *Blood Adv*. 9(24):6394-6401. 2025. PMID: 40991367.
173. McCurdy SR, Solomon SR, Shaffer BC, He M, Bolon YT, Blouin AG, Keyzner A, Socola FA, Ibrahim U, Zou J, Safah H, Saba N, Gadalla S, Perales MA, Paczesny S, Marsh SGE, Petersdorf EW, **Wang T**, Lee SJ, Fuchs EJ. Post-Transplant Cyclophosphamide Improves Survival in HLA-DPB1 Mismatched Unrelated Donor Allogeneic Transplantation. *Transplantation and Cellular Therapy*. 2025.
174. Nishitani M, Graham RA, **Wang T**, Devos J, Lee SJ, Spellman SR, Kitko CL, MacMillan ML, DeFilipp Z, Gray AN, Williams KM, Takahashi T, Schoettler ML, Hashem H, Rangarajan HG, Prestidge T, Ringden O, Hamilton BK, Sharma A, Nusrat R, El Jurdi N, Bhatt NS, Duncan CN, Qayed M. Impact of age on graft-versus-host disease and overall survival in pediatric hematopoietic cell transplant recipients. *Blood Adv*. 2026 Mar 24;10(6):2108-2121. PMID: PMC13045591
175. Saultz JN, Bolon YT, **Wang T**, Spellman SR, Lee SJ, He M, Camacho-Bydume C, Krishna C, Chowell D, Shaffer BC, Hsu KC, Paczesny S, Gadalla SM, Marsh SGE, Betts BC, Arrieta-Bolaños E. Higher HLA-DRB1 Evolutionary Divergence Is Associated with Reduced Relapse and Improved Survival after Matched Unrelated Hematopoietic Cell Transplantation. *Transplant Cell Ther*. 2026 Apr;32(4):434.e1-434.e11. PMID: PMC13059967
176. Ulschmid CM, Li X, **Wang T**, Logan BR, Pidala J, MacMillan ML, Kitko CL, Lee SJ, Spellman SR, Saber W. Validated clinical risk score for acute graft-versus-host disease in adult allogeneic hematopoietic cell transplantation. *Blood Adv*. 2026 Feb 24;10(4):1348-1360. PMID: PMC12927055